

CETUXIMAB FOR THE FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER

ADDENDUM FOR THE REPORT BY THE DECISION SUPPORT UNIT

Jonathan Tosh
School of Health and Related Research, University of Sheffield

20th May 2009

In the original DSU report dated 20th March 2009. Results were given in Table 9 page 21 for the cost-effectiveness model with a new DSU 16 week stopping rule applied. The treatment arms of Cetuximab+ FOLFOX and FOLFOX alone were run with a 43% rate of liver resection surgery and the resulting ICER of £24,022 per QALY was reported in the table.

The DSU also ran this stopping rule with liver resection surgery rates of 35% and 30%, but these were not reported. For completeness, the results of these changes to the model are provided in the revised Table 9 given below.

Table 9 – DSU Stopping Rule Results

Model	Comparators (£8,929 liver surgery cost)	Rate of Liver Resection Surgery								
		43%			35%			30%		
		Cost	QALY	ICER (per QALY)	Cost	QALY	ICER (per QALY)	Cost	QALY	ICER (per QALY)
Original Model	FOLFOX	£23,729	1.35	£36,489	£23,729	1.35	£48,329	£23,729	1.35	£60,583
	Cetuximab+FOLFOX	£42,880	1.87		£42,912	1.74		£42,933	1.66	
Treat Until Progression (updated original model)	FOLFOX	£23,729	1.41	£28,347	£23,729	1.41	£37,972	£23,729	1.41	£48,318
	Cetuximab+FOLFOX	£40,544	2.01		£40,451	1.85		£40,393	1.76	
Manufacturers 16 week stopping rule	FOLFOX	£23,729	1.41	£21,056	£23,729	1.41	£26,662	£23,729	1.41	£32,688
	Cetuximab+FOLFOX	£36,219	2.01		£35,471	1.85		£35,003	1.76	
New DSU 16 week stopping rule	FOLFOX	£23,729	1.41	£24,022	£23,729	1.41	£33,291	£23,729	1.41	£45,604
	Cetuximab+FOLFOX	£35,752	1.91		£34,962	1.75		£34,468	1.65	